Bringing new products to market is particularly challenging for companies in the life sciences sector. It can be a long and risk-filled pathway from the lab to the shelf, often requiring careful navigation through rigorous testing and regulatory compliance. To be viable and competitive, a company’s business plan must include a comprehensive and proactive intellectual property strategy—investors expect it and the marketplace demands it.
As IP attorneys and professionals working with innovators dedicated to creating life-saving and life-improving products, we see first-hand how deliberate and holistic IP asset protection makes the difference, particularly when it comes to enforcing rights to keep competitors at bay or defending against infringement allegations. We apply our science and engineering backgrounds and full scope IP-focused legal acumen, drawn from real life experience in litigation, prosecution, and counseling, to keep clients in business so they can keep making and collaborating on groundbreaking scientific discoveries and inspired technological applications.
Finnegan advises clients on virtually every intellectual property issue, whether it is related to patents, trademarks, copyrights, or trade secrets. Our practice comprises experienced attorneys and professionals who have an in-depth understanding of the complex legal, technical, regulatory, and business issues faced by industries innovating in the life sciences.
We help with:
Our Life Sciences practice includes attorneys and professionals with degrees in relevant scientific disciplines such as biology, chemistry, biochemistry, medicine, pharmacology, biomedical engineering, or electrical engineering, as well as attorneys with extensive experience in brand management and protection. Many joined Finnegan after holding positions in industry, at universities, or as examiners with the U.S. Patent and Trademark Office.
Advancements in artificial intelligence (AI) present novel challenges for businesses looking to invest in intellectual property. Protecting those investments and understanding the innovation landscape is where Finnegan comes in.
Introduced nearly ten years ago, the Biologics Price Competition and Innovation Act (BPCIA) opened the door for companies to seek U.S. Food and Drug Administration (FDA) approval to manufacture and sell biosimilar or interchangeable versions of brand name biological products.
Finnegan works with biotech pioneers to develop and execute successful intellectual property strategies, including patenting ground-breaking advancements, enforcing patents in litigation, and defending against claims of infringement or ownership by others.
Success in Abbreviated New Drug Application (ANDA) litigation in the U.S. often begins months or even years before a case is filed. Whether you are anticipating receipt of a Paragraph IV notice letter or still in late-stage clinical trials, it is never too early to start preparation.
Consumers have access to an ever-growing number of affordable and portable devices designed to provide metrics and details about personal health and lifestyle. In an increasingly connected world, this type of information can be invaluable in helping healthcare professionals provide higher levels of care.
Finnegan has the legal experience and technical expertise to help clients address the many issues that arise in developing, protecting, and commercializing medical device and diagnostic inventions.
Even with billions of dollars invested in research and development, few drugs make it through clinical trials and stringent regulatory clearances necessary to get to market. For those that do, it is crucial that the companies have protected the intellectual property (IP) underlying new drugs and treatments.
Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products.
Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias.
Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers.
Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company.
[2020] UKSC 27, Appeal number: UKSC 2018/0131, Supreme Court of the United Kingdom
Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief.
At the PTAB Blog
Squires Issues Precedential Decision Clarifying Obviousness-Type Double Patenting Rejections
August 17, 2026
Federal Circuit IP Blog
July 8, 2026
Award/Ranking
Partner Jeffrey M. Jacobstein Named Finalist for New England Legal Awards
August 10, 2026
Award/Ranking
Finnegan Receives Tier 1 Rankings from Managing IP; More than 30 Attorneys Named 2026 IP Stars
July 30, 2026
Award/Ranking
Finnegan Shortlisted in 13 Categories at the 2026 LMG Life Sciences America Awards
July 15, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.